BIIB Biogen Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BIIB

Price (delayed)

$274.01

Market cap

$39.59B

P/E Ratio

13.07

Dividend/share

N/A

EPS

$20.96

Enterprise value

$42.79B

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. ...

Highlights
The EPS has soared by 101% YoY and by 7% from the previous quarter
Biogen's net income has surged by 96% YoY and by 6% QoQ
The gross profit is down by 11% year-on-year
Biogen's revenue has decreased by 7% YoY
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: https://www.biogen.com/
Peers: AMGN GILD ABBV PFE

Key stats

What are the main financial stats of BIIB
Market
Shares outstanding
144.49M
Market cap
$39.59B
Enterprise value
$42.79B
Valuations
Price to earnings (P/E)
13.07
Price to book (P/B)
2.95
Price to sales (P/S)
3.91
EV/EBIT
11.63
EV/EBITDA
9.91
EV/Sales
4.21
Earnings
Revenue
$10.17B
EBIT
$3.68B
EBITDA
$4.32B
Free cash flow
$1.72B
Per share
EPS
$20.96
Free cash flow per share
$11.86
Book value per share
$93.04
Revenue per share
$70.02
TBVPS
$116.69
Balance sheet
Total assets
$24.55B
Total liabilities
$11.17B
Debt
$6.61B
Equity
$13.4B
Working capital
$6.52B
Liquidity
Debt to equity
0.49
Current ratio
2.99
Quick ratio
2.15
Net debt/EBITDA
0.74
Margins
EBITDA margin
42.4%
Gross margin
77.6%
Net margin
29.9%
Operating margin
35.3%
Efficiency
Return on assets
12.4%
Return on equity
24.7%
Return on invested capital
21.7%
Return on capital employed
17.3%
Return on sales
36.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BIIB stock price

How has the Biogen stock price performed over time
Intraday
1.39%
1 week
4.9%
1 month
1.54%
1 year
27.48%
YTD
-1.05%
QTD
-1.05%

Financial performance

How have Biogen's revenue and profit performed over time
Revenue
$10.17B
Gross profit
$7.9B
Operating income
$3.59B
Net income
$3.05B
Gross margin
77.6%
Net margin
29.9%
Biogen's operating margin has soared by 122% YoY
Biogen's net margin has soared by 111% YoY and by 8% from the previous quarter
BIIB's operating income has surged by 106% year-on-year
Biogen's net income has surged by 96% YoY and by 6% QoQ

Growth

What is Biogen's growth rate over time

Valuation

What is Biogen stock price valuation
P/E
13.07
P/B
2.95
P/S
3.91
EV/EBIT
11.63
EV/EBITDA
9.91
EV/Sales
4.21
The EPS has soared by 101% YoY and by 7% from the previous quarter
The P/E is 17% below the last 4 quarters average of 15.7 and 14% below the 5-year quarterly average of 15.2
The equity has grown by 23% YoY and by 4.9% from the previous quarter
BIIB's price to book (P/B) is 22% lower than its 5-year quarterly average of 3.8 but 5% higher than its last 4 quarters average of 2.8
The stock's price to sales (P/S) is 18% more than its last 4 quarters average of 3.3 and 6% more than its 5-year quarterly average of 3.7
Biogen's revenue has decreased by 7% YoY

Efficiency

How efficient is Biogen business performance
The ROS has soared by 148% YoY but it has contracted by 3.5% from the previous quarter
The ROIC has soared by 141% YoY but it has contracted by 5% from the previous quarter
Biogen's return on assets has surged by 91% YoY and by 5% QoQ
The ROE has soared by 69% YoY

Dividends

What is BIIB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIIB.

Financial health

How did Biogen financials performed over time
The total assets is 120% more than the total liabilities
The current ratio has soared by 63% YoY and by 20% from the previous quarter
The company's quick ratio has surged by 60% YoY and by 22% QoQ
Biogen's debt is 51% less than its equity
The debt to equity has decreased by 30% YoY and by 6% from the previous quarter
The equity has grown by 23% YoY and by 4.9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.